GCP
TRVI icon

GSA Capital Partners’s Trevi Therapeutics TRVI Stock Holding History

GSA Capital Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-43,506
Closed -$398K – 2094
2025
Q3 		$398K Buy
+43,506
New +$326K 0.03% 1010
2025
Q1 		– Sell
-120,212
Closed -$495K – 2083
2024
Q4 		$495K Sell
120,212
-2,235
-2% -$7.15K 0.04% 897
2024
Q3 		$409K Buy
+122,447
New +$364K 0.03% 1044

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

GSA Capital Partners's TRVI Position: Q4 2025 in Review

GSA Capital Partners sold out of Trevi Therapeutics (TRVI) in Q4 2025, closing a stake of 43,506 shares — an estimated $398K sold.

GSA Capital Partners first reported a position in TRVI in Q3 2024 and held it in 3 quarters. The position peaked at $495K in Q4 2024. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • GSA Capital Partners reported no remaining Trevi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 43,506 Trevi Therapeutics shares in Q4 2025, an estimated $398K.
  • GSA Capital Partners first reported a position in Trevi Therapeutics in Q3 2024 and held it in 3 quarters.
  • GSA Capital Partners's Trevi Therapeutics position peaked at $495K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.